Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H2 2016
SKU ID :GMD-10288715 | Published Date: 14-Sep-2016 | No. of pages: 76Description
TOC
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) Overview 9
Therapeutics Development 10
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Stage of Development 10
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Therapy Area 11
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Indication 12
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Companies 16
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Products under Development by Universities/Institutes 18
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development 26
Array BioPharma Inc. 26
Astellas Pharma Inc. 27
AstraZeneca Plc 28
Chiesi Farmaceutici SpA 29
Chroma Therapeutics Limited 30
Eli Lilly and Company 31
GlaxoSmithKline Plc 32
Synovo GmbH 33
Toray Industries, Inc. 34
Zocere, Inc. 35
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles 36
ARRY-797 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AS-1940477 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CHF-6297 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CHR-5623 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
losmapimod - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ralimetinib mesylate - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Recombinant Peptide To Inhibit MAPK14 For Ischemic Stroke - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Inhibit p38 MAP Kinase for Undisclosed Indication - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
SYD-003 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
VX-745 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Projects 55
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products 61
Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Featured News & Press Releases 63
Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress 63
Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress 64
Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor 64
Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study) 65
Jul 15, 2015: Zocere's Brain Saving” Drug Issued U.S. Patent 65
Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease 66
Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase 67
Oct 14, 2014: Zocere Showcases “Brain Saving” Drug at Life Sciences Summit in New York City 67
Oct 01, 2014: Zocere’s Stroke Drug to Be Featured at BIO Investor Forum 68
Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 68
Nov 06, 2012: Array BioPharma To Present Phase II Results Of ARRY-797 At 2012 American College Of Rheumatology Annual Meeting 69
Jul 31, 2012: Array BioPharma's Osteoarthritis Drug Meets Primary Endpoint In Phase II Trial 70
Jul 08, 2009: Array BioPharma Announces Top-Line Results In Two Phase I Clinical Trials 71
Oct 26, 2008: Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity in a Phase II Trial 72
May 07, 2008: Array BioPharma Presents Additional Positive Phase II Results Of ARRY-797 In Inflammatory Pain Clinical Trial At The American Pain Society's Annual Scientific Meeting 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76
Tables & Figures
List of Tables
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Array BioPharma Inc., H2 2016 26
Pipeline by Astellas Pharma Inc., H2 2016 27
Pipeline by AstraZeneca Plc, H2 2016 28
Pipeline by Chiesi Farmaceutici SpA, H2 2016 29
Pipeline by Chroma Therapeutics Limited, H2 2016 30
Pipeline by Eli Lilly and Company, H2 2016 31
Pipeline by GlaxoSmithKline Plc, H2 2016 32
Pipeline by Synovo GmbH, H2 2016 33
Pipeline by Toray Industries, Inc., H2 2016 34
Pipeline by Zocere, Inc., H2 2016 35
Dormant Projects, H2 2016 55
Dormant Projects (Contd..1), H2 2016 56
Dormant Projects (Contd..2), H2 2016 57
Dormant Projects (Contd..3), H2 2016 58
Dormant Projects (Contd..4), H2 2016 59
Dormant Projects (Contd..5), H2 2016 60
Discontinued Products, H2 2016 61
Discontinued Products (Contd..1), H2 2016 62
List of Figures
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Top 10 Indication, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 24
Companies
Array BioPharma Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Chiesi Farmaceutici SpA
Chroma Therapeutics Limited
Eli Lilly and Company
GlaxoSmithKline Plc
Synovo GmbH
Toray Industries, Inc.
Zocere, Inc.
- PRICE
-
$3500$10500